Recent Stock Performance and Business Context

Corvus Pharmaceuticals (CRVS) has drawn investor attention after a period of sharp share price swings, with the stock down 2.7% over the past day and 4.2% over the past week.

Those short term moves sit alongside a decline of 21.9% over the past month and 31.1% over the past 3 months, while the stock shows a year to date gain of 65% and a 1 year total return close to 200%.

At a share price of $12.08, Corvus Pharmaceuticals shows fading short term momentum after recent declines in share price returns, despite a very large 1 year total shareholder return and strong multi year total shareholder returns.

If this kind of high risk biotech story interests you, it can be useful to compare it with other healthcare stocks using our screener of 40 healthcare AI stocks

With Corvus trading at $12.08 against an analyst price target of $33.33, the stock appears to trade at a steep discount on paper. The key question is whether this represents a genuine opportunity or whether the market is already factoring in future growth.

Most Popular Narrative: 65.5% Undervalued

At a last close of $12.08 against a narrative fair value of $35, Corvus Pharmaceuticals is framed as heavily discounted, with that gap hinging on ambitious long range projections.

Corvus reports cash, cash equivalents and marketable securities of US$65.7 million and currently expects this to fund operations into the fourth quarter of 2026. This provides a runway to reach key readouts like the Cohort 4 extension data, Phase II atopic dermatitis progress and interim PTCL data, events that could influence future revenue expectations, R&D efficiency and ultimately earnings power.

Curious what has to happen between now and those trial readouts to support that higher fair value number? The widely followed narrative leans on a rapid build in revenue, a clear path to healthier margins and an earnings multiple that assumes meaningful progress in the pipeline. The full breakdown explains how these moving parts fit together.

Result: Fair Value of $35 (UNDERVALUED)

However, this hinges on soquelitinib delivering clean data in key trials and on Corvus avoiding heavy dilution as it funds multiple studies through 2026.

Another View: What The P/B Ratio Is Saying

While the narrative fair value points to Corvus Pharmaceuticals looking 65.5% undervalued at $35, the current P/B ratio of 4.2x tells a different story when compared with the US Biotechs industry at 2.6x and peers at 3.5x. That premium suggests higher valuation risk if the ambitious growth path does not materialise in full. How comfortable are you with paying above peer and industry levels today?

Next Steps

With sentiment split between strong past returns and clear valuation questions, now is a good time to look under the hood yourself and act quickly while forming your own view by weighing the 1 key reward and 3 important warning signs

Looking for more investment ideas?

If Corvus has caught your attention, do not stop there. A broader watchlist can help you spot opportunities and manage risk across different types of stocks.

• Target potential value opportunities by scanning companies that appear mispriced on quality and fundamentals using the 47 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses with strong finances and less fragile balance sheets through the 62 resilient stocks with low risk scores.
• Hunt for underfollowed opportunities with solid fundamentals by checking the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.